Price to earnings forward of Apogee Therapeutics, Inc. – NASDAQ:APGE
This page from TradingView provides financial information for Apogee Therapeutics, Inc. under the NASDAQ:APGE ticker. It specifically highlights the "Price to earnings forward" metric and indicates that the market is currently closed with no trades. The content is primarily a placeholder for financial data, along with extensive navigational and copyright information related to TradingView and its data providers.
Enterprise value to EBITDA forward of Apogee Therapeutics, Inc. – NASDAQ:APGE
This article shows the enterprise value to EBITDA forward for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data point provided by TradingView, indicating a specific valuation metric for the company. The content itself is very minimal, primarily serving as a landing page for this financial figure within the TradingView platform.
Apogee Therapeutics | SCHEDULE 13G/A: Others
This article provides an SEC filing snippet for Apogee Therapeutics, specifically referencing a SCHEDULE 13G/A document. The content of the document itself is not provided, only its existence is noted.
Enterprise value to revenue forward of Apogee Therapeutics, Inc. – NASDAQ:APGE
This article focuses on the enterprise value to revenue forward for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data snippet or a headline from a financial platform like TradingView, providing a direct metric for the company.
APGE - Apogee Therapeutics Inc Revenue Breakdown
This article provides a detailed financial breakdown for Apogee Therapeutics Inc (APGE), including its stock performance, market capitalization, key financial ratios, and institutional ownership. It highlights that the company currently has no sales and is operating at a net loss, while also showing significant stock performance gains over various periods.
Price to sales forward of Apogee Therapeutics, Inc. – NASDAQ:APGE
This article focuses on the "Price to sales forward" metric for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical data, and forecasts. The page structure also highlights the extensive features and community aspects of the TradingView platform.
Apogee Therapeutics (APGE) CMO sells shares, exercises options under 10b5-1 plan
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported an option exercise and a related sale of company shares. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved exercising options for 4,125 shares at $22.86 each and selling 5,500 shares at an average price of $132.74. Following these trades, Dambkowski directly owns 177,873 shares and holds options for an additional 114,790 shares.
Apogee Therapeutics stock hits all-time high at 133.32 USD
Apogee Therapeutics' stock has reached an all-time high of $133.32, with a soaring 1-year return of nearly 200%, reflecting significant investor confidence. This surge comes amid news of an acquisition by AbbVie for $135.11 per share and ongoing strategic developments like antibody discovery agreements and leadership approvals. Despite the high, some analysis suggests the stock might be overvalued based on Fair Value metrics.
Biotech Gives SBIO Its Best Month Since 2023
The ALPS Medical Breakthroughs ETF (SBIO) experienced its best single month since December 2023, returning 18.7% in June, primarily driven by biotech stock performance. Key contributors included Apogee, Definium, and Oruka, with significant surges due to drug trial results and a major acquisition. The performance highlights the importance of clinical-stage exposure for biotech investors.
Form 144 APOGEE THERAPEUTICS INC For: 1 July By Investing.com
This article announces the filing of Form 144 for APOGEE THERAPEUTICS INC on July 1st. Form 144 is a notice of the intent to sell restricted securities. The article lists current market data for various indices, commodities, and bonds.
Carl Dambkowski (APGE) 10b5-1 sales total $3.5M on 06/22/2026
Carl Dambkowski, an insider at Apogee Therapeutics, Inc. (APGE), reported 10b5-1 sales totaling $3.5 million from 26,400 shares on June 22, 2026, as part of a Form 144 filing. The filing also disclosed earlier 10b5-1 sales in May and June 2026, as well as planned dispositions related to stock option exercises and Restricted Stock Awards. These transactions are procedural disclosures under Rule 10b5-1, indicating pre-arranged trading plans.
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. has announced its acquisition of Apogee Therapeutics for approximately $10.9 billion, paying $135.11 per share in cash. This strategic move aims to expand AbbVie's immunology portfolio and strengthen its presence in the respiratory therapeutic area, with the transaction expected to close in fiscal Q3 2026.
Apogee Therapeutics (APGE) CMO sells 26,400 shares in planned open-market trade
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 26,400 shares of common stock on June 22, 2026, for a weighted average price of $132.60 per share, totaling $3.50 million. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established in September 2025. Following the sale, Dambkowski directly holds 179,248 shares of the company.
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Apogee Therapeutics Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV) for $135.11 per share in cash. KSF queries whether this acquisition price and the underlying process are fair and adequate, or if the Company is being undervalued. Shareholders who believe the transaction undervalues Apogee Therapeutics are invited to contact KSF to discuss their legal rights.
Form 4 Apogee Therapeutics Inc For: 24 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Apogee Therapeutics Inc (APGE) for June 24. It indicates that the company's stock symbol is APGE and includes a slight percentage change in its value. The article provides financial context with various market data like indices, commodities, bonds, and shares, though it does not detail the specifics of the Form 4.
Apogee Therapeutics CMO Carl Dambkowski sells $3.5m in stock
Carl Dambkowski, CMO of Apogee Therapeutics (NASDAQ:APGE), sold 26,400 shares of company stock for approximately $3.5 million. The sale was executed near the stock's 52-week high, following a 209% return over the past year. Apogee Therapeutics is also in the process of being acquired by AbbVie for $10.9 billion, with analysts adjusting ratings in response.
Apogee Therapeutics : APGE
This article provides key financial and company information for Apogee Therapeutics Inc (APGE), a biotechnology firm specializing in treatments for atopic dermatitis and COPD. It highlights the company's focus on monoclonal antibodies like APG777 and APG808, founded in 2022. The page also features current stock data and links to related articles.
Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share
Apogee Therapeutics (NASDAQ: APGE) is being acquired in an all-cash merger by Andor Merger Co., a subsidiary of AbbVie Inc., for $135.11 per share. An investor group led by Fairmount Funds, owning close to 9.99% of Apogee, has entered a Voting Agreement to support the merger. This SEC filing details the terms of the merger, Fairmount's beneficial ownership, and the voting commitments made by the fund.
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
Apogee Therapeutics (NASDAQ:APGE) shares surged by 46.66% today following AbbVie's cash buyout offer of $135.11 per share, totaling $10.9 billion. The market expects the deal to close in Q3, with Apogee's treatments for inflammatory and immunological disorders set to bolster AbbVie's immunology pipeline. The Motley Fool Stock Advisor team did not include Apogee Therapeutics in their top 10 stock recommendations, despite its significant growth since its 2023 IPO.
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie announced its acquisition of Apogee Therapeutics for approximately $10.9 billion, paying $135.11 per share in cash. This acquisition significantly expands AbbVie's immunology portfolio with Apogee's diverse pipeline of clinical-stage candidates, including zumilokibart (APG777) for atopic dermatitis and APG273 for asthma, both targeting inflammatory diseases. The deal is expected to close in Q3 2026, subject to regulatory and shareholder approvals, and is anticipated to be accretive to AbbVie's adjusted diluted EPS starting in 2032.
AbbVie to acquire Apogee Therapeutics (NASDAQ: APGE) in $10.9B cash deal
AbbVie announced its acquisition of Apogee Therapeutics for approximately $10.9 billion in an all-cash deal, paying $135.11 per share. The acquisition aims to expand AbbVie's immunology pipeline, particularly with Apogee's lead asset, zumilokibart (APG777), for atopic dermatitis and asthma, and the APG273 combination program. The transaction is unanimously approved by both companies' boards and is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals.
AbbVie seals $10.9 billion deal to acquire biotech Apogee Therapeutics
AbbVie has announced its acquisition of Apogee Therapeutics for $10.9 billion, valuing the biotech at $135.11 per share in cash. The deal is expected to close in the third quarter of 2026. Michael Henderson serves as the CEO of Apogee Therapeutics.
AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie announced its acquisition of Apogee Therapeutics for $10.9 billion in cash, a move that aligns with AbbVie's historical focus on immunology. Apogee's lead drug, zumilokibart, is an immunology treatment that targets the inflammatory cytokine IL-13, with potential applications for atopic dermatitis and asthma. This acquisition continues a trend of larger pharmaceutical companies acquiring biotech firms.
AbbVie deepens immunology legacy in $10.9bn Apogee buyout
AbbVie plans to acquire Apogee Therapeutics for $10.9 billion, significantly bolstering its immunology portfolio. The deal centers on Apogee's zumilokibart, an injectable anti-IL-13 therapy with "mega-blockbuster peak sales potential" for atopic dermatitis, asthma, and eosinophilic oesophagitis. This acquisition highlights the increasing pharma interest in immunology, building on AbbVie's success with existing blockbuster drugs like Skyrizi and Humira.
Apogee, Paragon Partner on IL-31R Antibody Program
Apogee Therapeutics and Paragon Therapeutics have partnered on an IL-31R antibody program, with Apogee funding the research and development. The agreement involves a discovery phase for monospecific antibodies and a license granting Apogee exclusive worldwide rights, accompanied by potential milestone payments and royalties. An analyst has rated Apogee Therapeutics (APGE) stock as a Buy with a $130 price target, while TipRanks' AI Analyst, Spark, rates it Neutral.
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Apogee Therapeutics (NASDAQ: APGE) regarding a recently announced transaction with CRH, which values Apogee at approximately $10.9 billion. The firm is examining whether Apogee's board of directors is upholding its fiduciary duties to all shareholders, particularly given that the transaction offers $135.11 per share in cash and includes substantial benefits for Apogee insiders, while imposing a significant penalty for competing bids. Ademi LLP encourages affected shareholders to contact them for more information.
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push
AbbVie announced its acquisition of biotech Apogee Therapeutics for $10.9 billion, marking its largest buyout in over five years. This strategic move aims to bolster AbbVie's next-generation immunology pipeline, especially as it faces patent expirations for key drugs like Humira, Skyrizi, and Rinvoq. The acquisition gives AbbVie access to zumilokibart, an experimental treatment for inflammatory diseases like atopic dermatitis and asthma, which is seen as a potentially more convenient alternative to existing therapies.
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
AbbVie is reportedly close to acquiring Apogee Therapeutics for approximately $10.9 billion in cash, according to the Financial Times. This potential deal represents about a 60% premium over Apogee's closing share price on Thursday, with an announcement possibly coming as early as Monday. Apogee, a biotechnology company focused on inflammatory and immune diseases, previously secured significant financing from Blackstone Life Sciences for its lead eczema drug.
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
AbbVie (ABBV) is reportedly close to acquiring Apogee Therapeutics (APGE), a developer of inflammatory disease drugs, for approximately $10.9 billion in cash, according to the Financial Times. This potential deal would value Apogee at a roughly 60% premium to its closing share price on Thursday. The acquisition follows AbbVie's recent FDA approval for a rare blood cancer treatment, further strengthening its drug pipeline.
Apogee Therapeutics Inc (APGE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Apogee Therapeutics Inc's (APGE) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and has no recorded stock split events. The article presents real-time stock data and company financial information.
Apogee Therapeutics Inc (APGE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Apogee Therapeutics Inc (APGE). It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays various financial metrics for APGE, including market cap, and stock performance.
Number of shareholders of Apogee Therapeutics, Inc. – NASDAQ:APGE
This article provides financial information for Apogee Therapeutics, Inc. (NASDAQ: APGE), focusing specifically on the number of shareholders. It presents a table showing the period, value, change, and change percentage related to shareholder data. The content is sourced from TradingView, which aggregates market data from ICE Data Services and FactSet.
Apogee Therapeutics Inc (APGE) Institutional Confidence
This article provides details on the institutional confidence in Apogee Therapeutics Inc (APGE), showcasing significant institutional shareholders and changes in their holdings. Key institutional investors like T. Rowe Price Investment Management, Inc. and Fidelity Management & Research Company LLC have substantial shares, with many increasing their positions, indicating growing confidence. The stock's current market performance is also noted, with a 2.61% increase during market hours.
Apogee Therapeutics Inc (APGE) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Apogee Therapeutics Inc (APGE), detailing analyst ratings, target prices, and EPS estimates. Most analysts recommend a "Buy" for APGE, projecting a target price of $119.50, which represents a 35.29% upside. The report includes a comparison with peer companies based on analyst ratings and discusses recent and future EPS expectations.
Apogee Therapeutics CEO Michael Henderson sells $1.67m in stock
Apogee Therapeutics CEO Michael Henderson sold approximately $1.67 million worth of company stock on June 10, 2026, as part of a pre-arranged trading plan. This sale of 19,000 shares comes as the stock trades near its 52-week high, despite InvestingPro suggesting it might be overvalued. The biotechnology company has recently announced positive Phase 2 trial results for its eczema treatment and secured a significant financing deal with Blackstone Life Sciences.
Apogee Therapeutics CEO Michael Henderson sells $1.67m in stock
Apogee Therapeutics CEO Michael Henderson sold common stock worth approximately $1.67 million on June 10, 2026, through a pre-arranged trading plan. This sale occurred while the company's stock, APGE, was trading near its 52-week high, despite analysis suggesting it might be overvalued. The article also reviews recent positive news for Apogee Therapeutics, including successful Phase 2 trial results for its eczema treatment, a significant financing deal with Blackstone Life Sciences, and varying analyst price targets.
Apogee Therapeutics shareholders elect directors and approve proposals at annual meeting
Apogee Therapeutics (NASDAQ:APGE) held its 2026 Annual Meeting of Stockholders, where shareholders elected three Class III directors, ratified Ernst & Young LLP as the independent registered public accounting firm, and approved executive compensation in a non-binding advisory vote. The biotech company, with a $6.71 billion valuation, has seen its stock rise 111% over the past year, though InvestingPro suggests it may be overvalued. Recent news includes positive Phase 2 trial results for zumilokibart and a $1.3 billion financing deal with Blackstone Life Sciences.
Apogee Therapeutics (APGE) CEO sells 20,000 shares in planned trades, keeps over 1.09M
Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares of common stock on June 10, 2026, under a pre-established Rule 10b5-1 trading plan. These sales, executed in multiple transactions at weighted-average prices between $82.78 and $86.89 per share, totaled approximately $1.67 million. Following these transactions, Henderson retains direct ownership of 1,095,987 shares of Apogee common stock.
Apogee Therapeutics (NASDAQ: APGE) investors back board, pay and auditor
Apogee Therapeutics (NASDAQ: APGE) shareholders have approved all proposals at their 2026 Annual Meeting. Investors elected three Class III directors, ratified Ernst & Young LLP as their independent registered public accounting firm, and approved executive compensation on an advisory basis. The company reported 61,853,254 shares entitled to vote as of the April 15, 2026 record date.
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shah Nimish P
This document from Apogee Therapeutics is a SEC Form 4 filing, which details a statement of changes in beneficial ownership of securities for Director Nimish P. Shah. As a Form 4, it legally reports transactions made by company insiders.
Apogee Therapeutics (APGE) links 7,657-share option grant to director
Apogee Therapeutics, Inc. reported a grant of 7,657 stock options to director Tomas Kiselak, with an exercise price of $85.00 per share. This routine equity compensation vests on the one-year anniversary of the grant date, subject to Kiselak's continued service. Kiselak holds the option for investment vehicles managed by Fairmount Funds Management LLC and disclaims beneficial ownership, as does Fairmount, except to the extent of its pecuniary interest.
Venrock-linked director at Apogee (APGE) awarded 7,657 stock options
Apogee Therapeutics director Nimish P. Shah was granted 7,657 stock options with an exercise price of $85.00, expiring on June 9, 2036. These options vest on the one-year anniversary of the grant date and are held for the sole benefit of Venrock Management, LLC. Shah is considered an indirect beneficial owner only to the extent of his pecuniary interest.
Apogee Therapeutics (APGE) director receives stock options for 7,657 shares
Apogee Therapeutics director Mark C. McKenna was granted stock options for 7,657 shares at an exercise price of $85.00 per share. These options will vest on the one-year anniversary of the June 9, 2026 grant date, provided his continued service, and are set to expire on June 9, 2036. This transaction is categorized as a grant or award acquisition rather than an open-market purchase.
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding
Apogee Therapeutics is advancing its IL-13-targeting antibody, zumilokibart, into Phase 3 trials for moderate-to-severe atopic dermatitis in the second half of the year, supported by promising Phase 2 data and up to $1.3 billion in funding from Blackstone Life Sciences. The company also plans to expand zumilokibart into asthma and eosinophilic esophagitis, and is exploring combination programs, aiming for a potential 2029 launch in atopic dermatitis. Apogee believes zumilokibart's strong efficacy, convenient dosing schedule, and favorable itch profile could position it as a first-line treatment in a growing market.
TD Asset Management Inc Has $9.76 Million Position in Apogee Therapeutics Inc. $APGE
TD Asset Management Inc. significantly increased its stake in Apogee Therapeutics Inc. by 55.3% in the fourth quarter, bringing its total holdings to 129,290 shares valued at $9.76 million. Despite recent insider selling by executives, institutional investors maintain a substantial 79.04% ownership in the company, which recently exceeded analyst earnings estimates. Analysts have a "Moderate Buy" consensus rating for Apogee Therapeutics, with an average price target of $114.56.
Why Apogee Therapeutics (APGE) Is Up 8.0% After Phase 2 Win And $1.3 Billion Blackstone Deal
Apogee Therapeutics saw an 8.0% stock increase following positive Phase 2 data for its anti-IL-13 antibody, zumilokibart, in atopic dermatitis and a $1.3 billion financing deal with Blackstone Life Sciences. This development strengthens zumilokibart's potential as a key asset, easing funding concerns and paving the way for Phase 3 trials. However, the investment narrative now heavily relies on this single asset's performance, and the company's valuation report suggests it may be overvalued.
RBC Raises Price Target on Apogee Therapeutics to $97 From $82, Keeps Sector Perform, Speculative Risk
RBC Capital Markets has increased its price target for Apogee Therapeutics (NASDAQ: APGE) from $82 to $97 while maintaining a "Sector Perform" rating with a "Speculative Risk" caveat. This adjustment reflects an updated valuation by the firm.
APGE Maintained by RBC Capital -- Price Target Raised to $97.00
RBC Capital has maintained a 'Sector Perform' rating for Apogee Therapeutics (APGE) but raised its price target to $97.00 from $82.00, indicating a cautious optimism for the company's growth potential. Despite this, Apogee Therapeutics has a low GF Score™ of 14/100 due to weaknesses in profitability, and insider activity shows a $5.2 million sell-off in the last three months, suggesting investors should proceed with caution.
RBC Raises Price Target on Apogee Therapeutics to $97 From $82, Keeps Sector Perform, Speculative Risk
RBC has increased its price target on Apogee Therapeutics Inc. (APGE) to $97 from $82, while maintaining a "Sector Perform" rating with a "Speculative Risk" designation. This adjustment follows news regarding Apogee Therapeutics' shares reflecting atopic dermatitis prospects and recent financial activities by the company. The article also mentions other analyst adjustments and a significant financing collaboration with Blackstone Life Sciences.
Apogee Therapeutics (APGE) CMO trades stock under Rule 10b5-1 plan
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), exercised stock options for 4,125 shares and subsequently sold 5,500 shares at $78.71 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Dambkowski directly holds 205,648 shares of common stock and retains options for 118,915 additional shares. The sale, adopted on September 22, 2025, represents a small portion of his overall holdings.
